Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DWP-450 · 1 trial · 1 indication
The primary safety analysis was the calculation of the proportion of subjects with at least one adverse event that occurred from Day 0 through Day 365.
| Arm | Type | Description |
|---|---|---|
| Botulinum toxin, Tyoe A | EXPERIMENTAL | DWP-450 (Botulinum toxin, Type A) |
| Name | Type | Description |
|---|---|---|
| DWP-450 (Botulinum purified neurotoxin, Type A) | BIOLOGICAL | Botulinum toxin, Type A |
Inclusion Criteria: * Subjects must be an adult 18 years of age and over * Subject is able to provide informed consent and comply with study instructions * Subject has moderate-to-severe glabellar lines on maximum frown as assessed by the investigator and subject using the GLS * Subject is willing ...
DWP-450 is used for the treatment of glabellar frown lines, the vertical wrinkles that appear between the eyebrows. It is being developed as a dermatology treatment for this cosmetic indication.
DWP-450 is a monoclonal antibody that targets botulinum toxin type A. It is designed to address glabellar frown lines by targeting this toxin, which is responsible for the muscle contractions that cause these wrinkles.
DWP-450 is being developed by Evolus, Inc., a company publicly traded under the ticker symbol EOLS. Evolus is advancing this product for the treatment of glabellar frown lines.
DWP-450 is in Phase 2 clinical development. It is an investigational product and has not been approved by regulatory authorities. One Phase 2 trial has been completed to evaluate its safety and efficacy.
DWP-450 has one completed clinical trial, identified as NCT02428608, titled 'Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006'. This Phase 2 study enrolled 570 participants in the United States.
DWP-450 is a formulation of botulinum toxin type A, specifically developed for treating glabellar frown lines. It is a monoclonal antibody targeting this toxin, and it is being studied as a potential treatment for this cosmetic condition.